MedTrace Logo

A Phase I Study of Pazopanib in Adult Patients With Liver Cancer

NCT00370513 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2017-11-17

No results posted yet for this study

Summary

Liver cancer is a good target for anti-angiogenic treatments such as pazopanib. The effect of pazopanib in patients with liver cancer are unknown. This study is designed to evaluate the safety, tolerability and best dose of pazopanib to be given to patient with liver cancer.

Conditions

  • Carcinoma, Hepatocellular

Interventions

DRUG

pazopanib

Pazopanib is a potent, multi-target receptor tyrosine kinase inhibitor of VEGFR.

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-06
Primary Completion
2009-04-08
Completion
2009-04-08

Countries

  • United States
  • Hong Kong
  • Taiwan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00370513 on ClinicalTrials.gov